A positive opinion from the European Medicines Agency (EMA) can validate a drug's scientific rationale and unlock development incentives that accelerate its path forward. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that it has received a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP) for its pipeline product dusquetide in the treatment of Behçet's disease.
“We are extremely pleased to have received the positive opinion from the COMP and look forward to the European Commission granting the orphan drug designation for the SGX945 program,” said Soligenix CEO and president Christopher J. Schaber, PhD. “Behçet’s disease is an area of unmet medical need.” The designation provides incentives that may include protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval.
Dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body’s innate immune system rather than suppress it outright. For patients living with rare inflammatory diseases, regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress.
The EMA’s positive opinion signifies an important step for Soligenix as it continues to advance the program. The company is developing dusquetide for the treatment of Behçet's disease, a rare systemic inflammatory disorder that causes recurrent oral and genital ulcers, skin lesions, and eye inflammation. Current treatment options are limited and often associated with significant side effects.
Orphan drug designation in the European Union provides several benefits, including scientific advice from the EMA, reduced fees for regulatory procedures, and market exclusivity for 10 years after approval. This can significantly reduce the cost and time required to bring a new therapy to patients.
Soligenix is a late-stage biopharmaceutical company focused on developing treatments for rare diseases and areas of unmet medical need. The company's pipeline includes products for cutaneous T-cell lymphoma, oral mucositis, and radiation protection, in addition to dusquetide for inflammatory diseases.
For more information about Soligenix, visit the company’s newsroom at https://ibn.fm/SNGX.
